ChartMill assigns a Buy % Consensus number of 83% to LTRN. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-02 | Lake Street | Initiate | Buy |
| 2024-04-25 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-08-10 | EF Hutton | Reiterate | Buy -> Buy |
| 2023-06-26 | EF Hutton | Maintains | Buy -> Buy |
| 2023-05-18 | HC Wainwright & Co. | Initiate | Neutral |
| 2023-03-21 | EF Hutton | Reiterate | Buy |
| 2023-02-15 | EF Hutton | Maintains | Buy |
| 2022-11-01 | EF Hutton | Initiate | Buy |
| 2022-03-11 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-02 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-07 | HC Wainwright & Co. | Initiate | Buy |
7 analysts have analysed LTRN and the average price target is 20.4 USD. This implies a price increase of 434.03% is expected in the next year compared to the current price of 3.82.
The consensus rating for LANTERN PHARMA INC (LTRN) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.